Skip to main content
Log in

Neomycin-sorbitol and lactulose in the treatment of acute portal-systemic encephalopathy

A controlled, double-blind clinical trial

  • Original Articles
  • Published:
The American Journal of Digestive Diseases Aims and scope Submit manuscript

Abstract

In a double-blind, randomized study the efficacy of lactulose was compared with neomycin-sorbitol in 45 episodes of acute nitrogenous portal-systemic encephalopathy (PSE) induced by dietary protein, azotemia, or gastrointestinal hemorrhage. All patients had underlying cirrhosis, and at the time of randomization had encephalopathy of at least grade 2 severity and arterial ammonia concentrations greater than 150 μg/100 ml. Two thirds of the patients in each group returned to normal mental status and more than 80% in each group showed at least one grade improvement in mental state. In addition, there was equivalent improvement in asterixis, in the performance of the Number Connection Test, in the electroencephalographic pattern, and in arterial ammonia concentration. The principal difference between the two groups was a greater reduction in stool pH after lactulose therapy than after neomycin-sorbitol therapy. One patient randomized to neomycin-sorbitol had to be withdrawn from the study because of persistent vomiting related to the administration of the medication. Otherwise there were no complications attributable to therapy in either group. These data suggest that neomycin-sorbitol and lactulose are equally effective in the treatment of acute nitrogenous portal-systemic encephalopathy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ingelfinger FJ: Editorial comment. Year Book of Medicine. PB Beeson, C Muschenheim, WB Castle, TR Harrison, FJ Ingelfinger, and PK Bondy (eds). Chicago, Year Book Medical Publishers, 1964–1965, pp. 591–592

    Google Scholar 

  2. Lande M, Clot-Paimboef C: Traitement des encephalopathies porto-caves par le lactulose. Presse Med 76:1675–1676, 1968

    Google Scholar 

  3. Fung WP, Khoo OT: Treatment of chronic hepatic encephalopathy with lactulose. Med J Aust 2:160–163, 1968

    Google Scholar 

  4. Rottiers R, van Egmond J, Verbruggen R, Dierick G, Vermeulen A, DeGroote J, Standaert L, Demeulenaere L: Cirrhosis, hyperammonemia and lactulose. Tijdschr Gastroenterol 11:123–129, 1968

    Google Scholar 

  5. Elkington SG, Floch MH, Conn HO: Lactulose in the treatment of chronic portal-systemic encephalopathy. A doubleblind clinical trial. N Engl J Med 281:408–412, 1969

    Google Scholar 

  6. Ma MH, McLeod JG, Blackburn CRB: Longterm treatment of portal-systemic encephalopathy with lactulose. Aust Ann Med 18:117–123, 1969

    Google Scholar 

  7. Gauthier A, Camatte R, Remacle J, Mathiew C, Torrent M: Treatment of chronic hepatic encephalopathy with lactulose. Based on 30 cases. Arch Fr Mal App Dig 59:521, 1970

    Google Scholar 

  8. Geffroy Y, Segrestin M, Geffroy PY: Lactulose in the treatment of chronic portacaval encephalopathy—a propos of 20 cases. Therapeutique 46:897–901, 1970

    Google Scholar 

  9. Siebner H, Missmahl HP: Behandlung der hepatischen encephalopathie mit lactulose. Dtsch Med Wochenschr 95:1309–1312, 1970

    Google Scholar 

  10. Zeegen R, Drinkwater JE, Fenton JCB, Vince A, Dawson AM: Some observations on the effects of treatment with lactulose on patients with chronic hepatic encephalopathy. Q J Med 39:245–263, 1970

    Google Scholar 

  11. Bircher J, Haemmerli UP, Scollo-Lavizzari G, Hoffmann K: Treatment of chronic portal-systemic encephalopathy with lactulose. Report of six patients and review of the literature. Am J Med 51:148–159, 1971

    Google Scholar 

  12. Salvagnini M, Modena C, Negrin P, Ossi E, D'Angello A, Meani A, Naccarato R: Preliminary results with lactulose (1,4-β-galactosido-fructose) in the protracted treatment of systemic-portal encephalopathy. Clin Ter 63:317–336, 1972

    Google Scholar 

  13. Germain L, Frexions J, Louis A, Ribet A: Double-blind study of lactulose in 18 patients suffering from chronic hepatic encephalopathy after portocaval shunt. Arch Fr Mal App Dig 62:293–302, 1973

    Google Scholar 

  14. Rodgers JB Jr, Kiley JE, Balint JA: Comparison of results of long-term treatment of chronic hepatic encephalopathy with lactulose and sorbitol. Am J Gastroenterol 60:459–465, 1973

    Google Scholar 

  15. Eisenburg J, Grunst HJ, Holl J: Effect of lactulose on blood ammonia levels in patients with chronic cirrhosis encephalopathy and after portocaval shunt operation. Recent Progress in Ammonia Metabolism. M Imler and I Szam (eds). Baden-Baden, Verlag Gerhard Witzstrock, 1974, pp 178–187

    Google Scholar 

  16. Reikowski H, Reikowski J, Muting D: Effect of lactulose long-term treatment on increased ammonia levels in the blood and serum phenol values in 36 patients with cirrhosis of the liver. Recent Progress in Ammonia Metabolism. M Imler and I Szam (eds). Baden-Baden, Verlag Gerhard Witzstrock, 1974, pp. 174–177

    Google Scholar 

  17. Seidlova V: Lactulose in the treatment of chronic portal-systemic encephalopathy. (Laktuloza va lecbe chronickych portosystemickych encefalopatii.) Cesk Gastroenterol Vyz 28:201–207, 1974

    Google Scholar 

  18. Pirotte J, Guffens JM, Devos J: Comparative study of basal arterial ammonemia and of orally-induced hyperammonemia in chronic portal systemic encephalopathy, treated with neomycin, lactulose, and an association of neomycin and lactulose. Digestion 10:435–444, 1974

    Google Scholar 

  19. Conn HO, Leevy CM, Vlachevic ZR, Rodgers JB, Maddrey WC, Seeff L, Levy LL: A comparison of lactulose and neomycin in the treatment of portal-systemic encephalopathy: A double-blind controlled trial. Gastroenterology 72:573–583, 1977

    Google Scholar 

  20. Demeulenaere L, Rottiers R, van Egmond J, Lacres R, Dierick G, Verbruggen R: Traitement par lactulose de l'hyperammoniemie paroxystique spontanee ou provoquee et de l'hyperammoniemie chronique chez le cirrhotique. Probl Reanim 5:855–868, 1969

    Google Scholar 

  21. Simmons F, Goldstein H, Boyle JD: A controlled clinical trial of lactulose in hepatic encephalopathy. Gastroenterology 59:827–832, 1970

    Google Scholar 

  22. Fessel JM, Conn HO: Lactulose in the treatment of acute hepatic encephalopathy. Am J Med Sci 266:103–110, 1973

    Google Scholar 

  23. Conn HO: Les dilemmes d'une experimentation clinique: L'emploi du lactulose dans l'encephalopathie porto-cave. Union Med Can 103:2058–2060, 1974

    Google Scholar 

  24. Seligson D, Hirahara K: The measurement of ammonia in whole blood, erythrocytes, and plasma. J Lab Clin Med 49:962–974, 1957

    Google Scholar 

  25. Conn HO: The trailmaking and number connection tests in the assessment of mental state in portalsystemic encephalopathy. Am J Dig Dis 22:541–550, 1977

    Google Scholar 

  26. Agostini L, Down PF, Murison J, Wrong OM: Faecal ammonia and pH during lactulose administration in man: Comparison with other cathartics. Gut 13:859–866, 1972

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Additional information

A number of fellows and other colleagues who were coinvestigators in and co-authors of this study are listed alphabetically: Simon Bar-Meir, Joel Bessoff, George A. Cohen, J. Michael Fessel, Jay Frankel, Prakash H. Joshi, Lewis L. Levy, Milton Mutchnick, Donald Petroski, Michael Phillips, and Ned Snyder.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Atterbury, C.E., Maddrey, W.C. & Conn, H.O. Neomycin-sorbitol and lactulose in the treatment of acute portal-systemic encephalopathy. Digest Dis Sci 23, 398–406 (1978). https://doi.org/10.1007/BF01072921

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01072921

Keywords

Navigation